In 2017 Institut Curie launched a study for children and adolescents with high-risk cancer.
MICCHADO, led by Gudrun Schleiermacher, head of the Translational Research in Pediatric Oncology team (RTOP) endorsed by SIRIC in 2013. This new study aims to understand the aggressiveness and the resistance of cancer cells to treatment.
The study will rely on a characterization of the immune response of the patient and on the molecular analysis of the tumor. Researchers will also follow the evolution of the disease over time via circulating tumor DNA through iterative blood sampling.
High-throughput sequencing technologies are at the heart of the project including the Institut Curie NGS platform.
The ultimate goal is to be able to develop new therapeutic approaches as soon as treatment begins or as soon as resistance appears.